Glenmark Pharmaceuticals Limited Share Price & Technical Analysis
GLENMARK · ₹2,351 (+0.62%)
Healthcare / Drug Manufacturers - Specialty & Generic
₹2,351
+0.62%
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertensio…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-2% return in May, 7% avg return in past 3 year May month.
19% return in 2026, 57% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | 10% | 1% | 10% | -2% | – | – | – | – | – | – | – | 19% |
| 25 | -10% | -11% | 21% | -10% | 6% | 20% | 22% | -10% | 2% | -3% | 3% | 4% | 33% |
| 24 | 7% | 1% | 4% | 10% | 9% | 5% | 19% | 18% | -4% | 1% | -10% | 5% | 65% |
| 23 | -9% | 11% | 8% | 21% | 6% | 13% | 17% | -4% | 11% | -12% | 4% | 9% | 74% |
| 22 | -8% | -8% | 0% | -1% | -10% | -2% | -1% | -3% | 4% | 4% | 5% | -3% | -23% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
₹636.96B
P/E ratio
59.73
52W high
₹2,474
52W low
₹1,376
Volume
4,78,962
Beta
0.31
Related stocks in Healthcare
Ngl Fine-chem Ltd.
₹2,260
Frequently asked questions
- What is Glenmark Pharmaceuticals Limited share price today?
- Glenmark Pharmaceuticals Limited (GLENMARK) last traded around ₹2,351 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GLENMARK have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GLENMARK. Download the app for real-time alerts.
- How can I analyze Glenmark Pharmaceuticals Limited stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.